ClinicalTrials.gg
WithdrawnNCT01203371Updated Sep 9, 2026

Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS

A Phase 3 interventional study of Naftopidil and Tamsulosin in Hyperplasia, sponsored by Apsen Farmaceutica S.A.. Withdrawn at 1 site in Brazil. Open to male participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Apsen Farmaceutica S.A. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the effectiveness and safety of Naftopidil and Tamsulosin in the treatment of lower urinary tract symptoms through a comparative study of patients with benign prostatic hyperplasia.

Read the detailed description

Inclusion Criteria:

Men ≥ 50 years Signs and symptoms of BPH A total IPSS of ≥ 10 Prostate volume of ≥20 mL (estimated by ultrasonography) PVR > 150mL

02

Conditions studied

  • Hyperplasia

Keywords

  • naftopidil
  • symptoms of lower urinary tract
  • benign prostate hyperplasia
  • LUTS
03

In context

Hyperplasia

76 studies on the registry are indexed under Hyperplasia; 9 are open to participants now.

Browse Hyperplasia studies →

Lead sponsor

Apsen Farmaceutica S.A. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men ≥ 50 years
  • Signs and symptoms of BPH
  • IPSS of ≥ 10
  • Prostate volume of ≥ 20 mL
  • PVR > 150 mL

Exclusion criteria

Exclusion Criteria:

  • History of allergy to a AR antagonists
  • Treatment with antiandrogen drugs
  • Drugs with anticholinergic activity
  • Significant history of orthostatic hypotension
  • Concomitant neurological diseases
  • Known or suspected neurogenic bladder dysfunction
  • Carcinoma of the prostate or bladder
  • Previous surgery for BPH or bladder neck obstruction
  • History of recurrent UTI
  • Concomitant active UTI
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Naftopidil

    0,25 mg (2 weeks) and 0,50 mg (10 weeks)

    Drug: Naftopidil

  • Active comparator
    Tamsusolin

    0,4 mg/day

    Drug: Tamsulosin

Interventions

06

What researchers measure

Primary outcomes

  1. International Prostate Symptom Score

    Time frame: 2, 4, 8 and 12 weeks

Secondary outcomes

  1. Adverse Effect

    Time frame: 2, 4, 8 and 12 weeks

07

Study locations

1 site
  • Hospital das Clínicas da Faculdade de Medicina da USP
    São Paulo, São Paulo 05403-010, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2011 to primary completion in Sep 2011, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2010
First posted
Sep 16, 2010
StartActual
Jan 1, 2011
Primary completionActual
Sep 1, 2011
CompletionActual
Jan 1, 2012
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01203371
Lead sponsor
Apsen Farmaceutica S.A.
Responsible party
Sponsor
First posted
Sep 16, 2010
Start date
Jan 1, 2011
Primary completion
Sep 1, 2011
Completion
Jan 1, 2012
Last update
Sep 9, 2026

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naftopidil

Start the discussion